Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

6.580
-0.040-0.60%
Volume:4.46M
Turnover:30.50M
Market Cap:6.34B
PE:-20.05
High:7.130
Open:6.900
Low:6.550
Close:6.620
Loading ...

Company Profile

Company Name:
ASCLETIS-B
Exchange:
SEHK
Establishment Date:
2013
Employees:
231
Office Location:
12/F, Building D,198 Qidi Road, HIPARK,Xiaoshan District,Hangzhou,Zhejiang Province,China
Zip Code:
311200
Fax:
86 571 8538 9730
Introduction:
Ascletis Pharma Inc is an investment holding company mainly engaged in the research and development, production, and sales of pharmaceutical products. The Company focuses on viral diseases, non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC), and oncology. The company's product pipeline includes ASC22 for chronic hepatitis B functional cure, ASC10 for respiratory syncytial virus (RSV), ASC22 for human immunodeficiency virus (HIV) functional cure, ASC10 and ASC11 for COVID-19, ASC41 for NASH, ASC42 for PBC, ASC61 for solid tumors, ASC40 for moderate and severe acne, and others.